查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571579

肺部給藥系統市場規模、佔有率、趨勢分析報告：按產品、按應用、按最終用途、按地區、細分市場預測，2024-2030年

Pulmonary Drug Delivery Systems Market Size, Share & Trends Analysis Report By Product (Inhalers, Nebulizers, Accessories), By Application (Asthma, Cystic Fibrosis), By End-use, By Region And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

肺部給藥系統市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球肺部給藥系統市場規模將達到723.3億美元，2024年至2030年複合年成長率為4.6%。

慢性呼吸道疾病的盛行率不斷上升預計將推動肺部藥物輸送系統（PDDS）的採用。據世界衛生組織稱，全球有 2.35 億人患有氣喘。由於缺乏治療選擇，大多數與氣喘相關的死亡發生在低收入和中等收入國家。這顯示未來幾年對肺部給藥系統的潛在需求。

藥物傳輸領域的技術進步預計將對肺部藥物傳輸裝置市場產生正面影響。這些進步包括引入聚集囊泡技術、MDI 電子劑量計數器、粒子工程和超臨界流體技術。對新產品的需求不斷增加、生活方式的改變、易用性和設施的改進等因素預計將提供利潤豐厚的機會。

此外，公共和私人機構數量的增加也是推動肺部給藥裝置市場成長的主要因素。例如，亞太氣喘、氣喘和臨床免疫學協會 (APAAACI) 等組織致力於為過敏、氣喘和臨床免疫學的臨床和基礎研究提供資訊。此類措施預計將增加新興市場對呼吸藥物輸送設備的市場需求，並推動整體市場成長。

肺部給藥系統市場報告重點：

  • 2023 年，吸入器細分市場佔據最大市場佔有率，達到 62.8%。與循環到血液中的注射劑不同，吸入器將藥物直接輸送到肺部。
  • 霧化器領域預計在預測期內複合年成長率最快，達到 5.4%。
  • 2023 年，慢性阻塞性肺病(COPD) 細分市場佔據最大市場佔有率。慢性阻塞性肺病是一種慢性疾病，需要持續的治療和照護。
  • 預計氣喘細分市場在預測期內將以最快的複合年成長率成長。氣喘患者希望治療方法易於攜帶、易於使用並且可以每天使用。
  • 2023年，醫院和診所領域佔據市場主導地位。醫院和診所的醫生提供的治療可以幫助患者快速康復。
  • 北美肺部給藥系統市場佔主導地位，2023 年收益佔有率最大，為 32.0%。患有氣喘和 CODP 等慢性疾病患者數量不斷增加，推動了該地區市場的成長。
  • 亞太肺部給藥系統市場預計將顯著成長。氣喘患者和過敏性鼻炎患者數量的持續增加預計將成為推動市場成長的因素。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章肺部給藥系統市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 肺部給藥系統市場分析工具
    • 波特的分析
    • PESTEL分析

第4章肺給藥系統市場：產品評估與趨勢分析

  • 細分儀表板
  • 肺部給藥系統市場：2023年及2030年產品波動分析
  • 吸入器
  • 噴霧器
  • 配件

第5章肺部給藥系統市場：應用估計和趨勢分析

  • 細分儀表板
  • 肺部給藥系統市場：2023年及2030年應用變化分析
  • 氣喘
  • 囊腫纖維化
  • 慢性阻塞性肺病（COPD）
  • 過敏性鼻炎
  • 肺動脈高血壓
  • 其他

第6章肺部給藥系統市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 肺部給藥系統市場：2023 年和 2030 年最終用途變化分析
  • 醫院/診所
  • 日間手術中心 (ASC)
  • 居家護理
  • 其他

第7章肺給藥系統市場：區域估計與趨勢分析

  • 肺部給藥系統市場佔有率（按地區），2023 年和 2030 年，百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 最新趨勢與影響分析：主要市場參與企業
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • 3M
    • AstraZeneca
    • GSK plc.
    • Novartis AG
    • Koninklijke Philips NV
    • Boehringer Ingelheim International GmbH.
    • Teva Pharmaceutical Industries Ltd.
    • OMRON Healthcare, Inc.
    • PARI GmbH
    • Cipla
簡介目錄
Product Code: GVR-1-68038-587-8

Pulmonary Drug Delivery Systems Market Growth & Trends:

The global pulmonary drug delivery systems market size is expected to reach USD 72.33 billion by 2030, registering a CAGR of 4.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of chronic respiratory diseases is expected to boost the adoption of Pulmonary Drug Delivery Systems (PDDS). As per WHO, 235 million people suffer from asthma globally. Majority of the asthma-related deaths occur in middle- to low-income countries due to a lack of treatment options. This shows the potential demand for pulmonary drug delivery systems in the coming years.

Technological advancements in the field of drug delivery are expected to positively impact the pulmonary drug delivery devices market. These advancements include the incorporation of agglomerated vesicle technology, MDI electronic dose counter, particle engineering, and supercritical fluid technology. Rising demand for new products, changing lifestyle, ease of use, and better facilities are factors expected to provide lucrative opportunities.

Furthermore, a rise in the number of public and private organizations is another major factor propelling the growth of the pulmonary drug delivery devices market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market demand for respiratory drug delivery devices in developing regions, thereby boosting the overall market growth.

Pulmonary Drug Delivery Systems Market Report Highlights:

  • The inhalers segment accounted for the largest market share of 62.8% in 2023. Unlike injections which circulate in the bloodstream, inhalers administer medicine straight to the lungs.
  • The nebulizers segment is expected to register the fastest CAGR of 5.4% during the forecast period.
  • The Chronic Obstructive Pulmonary Disease (COPD) segment accounted for the largest market share in 2023. COPD is a chronic disease that requires continuous treatment and care.
  • The asthma segment is projected to grow at the fastest CAGR over the forecast period. Asthma patients look for treatment options that are easy to carry and use, in their everyday routines.
  • The hospitals & clinics segment dominated the market in 2023. The treatment offered by doctors in hospitals and clinics helps in speedy recovery of patients.
  • North America pulmonary drug delivery systems market dominated the market with the largest revenue share of 32.0% in 2023. The increasing cases of chronic diseases such as asthma and CODP is attributing to the market growth in the region.
  • Asia Pacific pulmonary drug delivery systems market anticipated to witness significant growth. The continuous increase in the number of asthmatic and allergic rhinitis patients are factors expected to propel the market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pulmonary Drug Delivery Systems Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Pulmonary Drug Delivery Systems Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Pulmonary Drug Delivery Systems Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pulmonary Drug Delivery Systems Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Inhalers
    • 4.3.1. Inhalers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Nebulizers
    • 4.4.1. Nebulizers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Accessories
    • 4.5.1. Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pulmonary Drug Delivery Systems Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pulmonary Drug Delivery Systems Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Asthma
    • 5.3.1. Asthma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cystic Fibrosis
    • 5.4.1. Cystic Fibrosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Chronic Obstructive Pulmonary Disease (COPD)
    • 5.5.1. Chronic Obstructive Pulmonary Disease (COPD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Allergic Rhinitis
    • 5.6.1. Allergic Rhinitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Pulmonary Arterial Hypertension
    • 5.7.1. Pulmonary Arterial Hypertension Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pulmonary Drug Delivery Systems Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pulmonary Drug Delivery Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals & Clinics
    • 6.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ambulatory Surgical Centers (ASCs)
    • 6.4.1. Ambulatory Surgical Centers (ASCs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Home Care
    • 6.5.1. Home Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Other End Use Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pulmonary Drug Delivery Systems Market: Regional Estimates & Trend Analysis

  • 7.1. Pulmonary Drug Delivery Systems Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. 3M
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. AstraZeneca
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. GSK plc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Novartis AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Koninklijke Philips N.V.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Boehringer Ingelheim International GmbH.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Teva Pharmaceutical Industries Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. OMRON Healthcare, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. PARI GmbH
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Cipla
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives